36 results on '"Lam, John S."'
Search Results
2. EDITORIAL COMMENT.
- Author
-
Lam, John S
- Published
- 2020
- Full Text
- View/download PDF
3. Surveillance for renal cell carcinoma: Why and how? When and how often?
- Author
-
Klatte, Tobias, Lam, John S., Shuch, Brian, Belldegrun, Arie S., and Pantuck, Allan J.
- Subjects
- *
RENAL cell carcinoma , *CANCER treatment , *CANCER patients , *POSTOPERATIVE care , *METASTASIS , *KIDNEY tumors , *KIDNEY surgery , *RADIOSCOPIC diagnosis , *CANCER relapse - Abstract
Abstract: Patient''s history, physical examination, laboratory tests, and radiographic evaluation are the cornerstones of postoperative surveillance. It has been shown that localized renal cell carcinoma (RCC) can recur in nearly all organs of the body, but most commonly in the lung, bone, liver, brain, and renal fossa. Lung metastases can be sensitively detected through radiographic evaluation. Treatment of lung metastases might prolong survival, which supports surveillance x-ray or computed tomography scans. Surgical treatment of early detected liver metastases and local recurrences may also prolong survival, which supports a close abdominal surveillance program. Brain and bone metastases are usually symptomatic when they occur, and their treatment is generally palliative. Hence, surveillance protocols do not usually include their routine radiographic evaluation. Because partial nephrectomy does not increase the risk of local recurrence over radical nephrectomy, we recommend identical surveillance for completely resected tumors regardless of surgical approach. The risk of recurrence after nephrectomy is generally related to tumor stage, tumor grade, and patient performance status. The majority of recurrences occur within the first 5 years after surgery, supporting a more intense surveillance strategy within the first 5 years. The University of California Integrated Staging System (UISS) combines TNM stage, Fuhrman grade, and performance status, and categorizes patients into 3 different risk groups. The current surveillance protocol at our institution is based on the UISS. It is expected that molecular markers such as p53 will allow more individualized surveillance strategies in the future. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
4. Prognostic factors and selection for clinical studies of patients with kidney cancer
- Author
-
Lam, John S., Klatte, Tobias, Kim, Hyung L., Patard, Jean-Jacques, Breda, Alberto, Zisman, Amnon, Pantuck, Allan J., and Figlin, Robert A.
- Subjects
- *
RENAL cancer , *CANCER patients , *RENAL cell carcinoma , *TUMORS - Abstract
Abstract: Over the past 2 decades, a greater understanding of the basic biology and genetics of kidney cancer has occurred. Surgical techniques have also evolved, and technological advances have made possible new methods of managing renal tumors. The most extensively used system to provide prognostic information for renal cell carcinoma (RCC) is currently the tumor, nodes, metastasis (TNM) staging system. Emerging data over the last few years has questioned whether further revisions are needed and if improvements can be made with the introduction of new, more accurate and predictive prognostic factors. The recent discovery of molecular tumor biomarkers are expected to revolutionize the staging of RCC and potentially lead to the development of new therapies based on molecular targeting. This review will examine the current staging modalities and prognostic factors associated with RCC as well as the selection of patients most likely to benefit from clinical trials. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
5. Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience
- Author
-
Lam, John S., Klatte, Tobias, Patard, Jean-Jacques, Goel, Rakhee H., Guillè, François, Lobel, Bernard, Abbou, Clement-Claude, De La Taille, Alexandre, Tostain, Jacques, Cindolo, Luca, Altieri, Vincenzo, Ficarra, Vincenzo, Artibani, Walter, Prayer-Galetti, Tommaso, Schips, Luigi, Zigeuner, Richard, Pantuck, Allan J., Figlin, Robert A., and Belldegrun, Arie S.
- Subjects
- *
TUMORS , *RENAL cell carcinoma , *DISEASES , *CANCER , *PATHOLOGY - Abstract
Abstract: Objective: To evaluate the prognostic role of tumour size in pathological stage T3a renal cell carcinoma (RCC) with fat invasion only and to assess whether this subgroup maintains its relevance over the other pathological stages. Methods: We retrospectively studied 2113 patients from eight international institutions who were treated by surgical resection for T2–4 RCC. Disease-specific survival (DSS) was evaluated with univariate and multivariate analyses. Results: Univariate analysis of patients with T3a RCC showed that tumour size was significantly associated with DSS (HR: 1.09, 95% CI: 1.05–1.12, p <0.001). An ideal cut-off of 7cm for these patients was identified with a scatter plot of Martingale residuals and tumour size. The two T3a groups were distinctly different with respect to clinicopathologic parameters (performance status, metastases, grade, histological subtype) and survival (p <0.001). Median survival time was not reached for patients with T2 and T3a≤7cm disease with a 5- and 10-yr DSS rate of 70% and 59% and 63% and 53%, respectively. Median survival time for patients with T3a>7cm, T3b, T3c, and T4 disease was 54, 46, 21, and 11 mo, respectively, with 5- and 10-yr DSS rates of 46% and 36%, 46% and 36%, 34% and 0%, and 16% and 14%, respectively. Conclusions: Our data indicate that tumour size is an important factor for predicting outcome of patients with T3a RCC with fat invasion only. Our findings should merit consideration during the next revision of the TNM classification. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
6. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score.
- Author
-
Lam, John S., Seligson, David B., Hong Yu, Ali Li, Eeva, Mervi, Pantuck, Allan J., Gang Zeng, Horvath, Steve, and Belldegrun, Arie S.
- Subjects
- *
ENDONUCLEASES , *GENE expression , *PROSTATE cancer , *DNA microarrays , *CANCER cells , *IMMUNOHISTOCHEMISTRY - Abstract
OBJECTIVE To investigate the expression and potential clinical usefulness of structure-specific flap endonuclease 1 (FEN-1) in human primary prostate cancer using tissue microarray technology, as FEN-1 was recently identified to be overexpressed in CL1.1, the most aggressive clone generated from the hormone-refractory prostate cancer cell line CL1. MATERIALS AND METHODS Immunohistochemistry was performed on tissue microarrays constructed from paraffin-embedded specimens of primary prostate cancer from 246 patients who had had a radical prostatectomy. Prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH) and normal prostate epithelium were represented on the array. FEN-1 nuclear expression was scored based on the percentage of target cells staining positively, and correlated with Gleason score, preoperative prostate-specific antigen (PSA) level and pathological stage. The time to PSA recurrence was also analysed. RESULTS The mean expression of FEN-1 was significantly higher in cancer (36.7%) than in normal (13.2%), BPH (4.5%) and PIN (15.4%) specimens ( P < 0.001). FEN-1 expression was significantly correlated with Gleason score (ó = 0.23, P = 0.002). A higher preoperative serum PSA level ( P = 0.015), Gleason score ≥ 7 ( P < 0.001), seminal vesicle invasion ( P < 0.001) and capsular involvement ( P = 0.004) were associated with PSA recurrence, whereas FEN-1 expression was not. In a multivariate analysis, only Gleason score ≥ 7 ( P < 0.001), seminal vesicle invasion ( P = 0.005) and capsular involvement ( P = 0.009) were retained as independent predictors for PSA recurrence. CONCLUSIONS FEN-1 is overexpressed in prostate cancer compared with matched normal prostate, and its expression increases with tumour dedifferentiation, as shown by increasing Gleason score. These results suggest that FEN-1 might be a potential marker for selecting patients at high risk, and a potential target for prostate cancer diagnosis and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
7. Long-term outcomes of the surgical management of renal cell carcinoma.
- Author
-
Lam, John S., Belldegrun, Arie S., and Pantuck, Allan J.
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *CANCER cells , *LAPAROSCOPY , *ADRENALECTOMY , *TOMOGRAPHY , *METASTASIS , *PROGNOSIS - Abstract
It has been 35 years since the radical nephrectomy was standardized by the work of Robson et al. (J Urol 101:297–301, 1969). Despite being based on a retrospective review of only 88 cases operated upon over a span of 15 years, this publication was an important milestone in the attempt to create uniformity in the staging of Renal cell carcinoma (RCC), and the measurement of surgical outcomes for RCC. Although this manuscript forms the basis for our contemporary measurement of the long-term results of RCC surgery and set the standard to which the entire subsequent literature was compared, contemporary research subsequently has questioned many of Robson’s conclusions regarding RCC. In Robson’s era, the majority of patients presented with large, symptomatic tumors, pre-operative staging was imprecise, and many patients had locally advanced disease at the time of surgery: of the 88 patients in Robson’s series, 75% were managed through a thoracoabdominal incision. Since that time, advances in renal imaging and clinical staging have led to the increased detection of incidental, lower stage, organ-confined tumors more amendable to expanded surgical options. Surgical techniques have evolved and technological advances have made possible new methods of managing renal tumors in situ that have emphasized a transition from radical to less extirpative approaches. In addition, understanding of the basic biology and genetics of kidney cancer has led to improved prognostication and the development of effective immunotherapies for advanced disease. The current concepts and long-term outcomes of the surgical management of RCC will be reviewed to help elucidate some of these changes, from the evolution of open to laparoscopic to percutaneous, from radical to partial to ablative approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. Stem cells in prostate and prostate cancer development
- Author
-
Lam, John S. and Reiter, Robert E.
- Subjects
- *
STEM cells , *CANCER cells , *PROSTATE cancer , *CELL populations - Abstract
Abstract: Most cancers comprise a heterogenous population of cells with marked differences in their potential to proliferate as well as the ability to reconstitute the tumor upon transplantation. Cancer stem cells are a minor population of tumor cells that possess the stem cell property of self-renewal. Dysregulation of stem cell self-renewal is a likely requirement for the development of cancer. Cell signaling pathways shared by stem cells and cancer cells lend further evidence for a possible link between these 2 populations of cells. Study of the differentiation pathways of normal and abnormal prostate growth has led to the development of a stem cell model for prostate cancer. The basal layer of the normal prostate is believed to be populated by prostate epithelial stem cells and a population of transit-amplifying cells intermediate in differentiation to the stem and fully differentiated cells. There is recent evidence suggesting that prostate cancer occurs from malignant transformation of stem/progenitor cells, thereby resisting apoptosis and spawning proliferation. This new model for prostate cancer will have significant ramifications for the way this disease is studied and treated. Furthermore, through targeting the prostate cancer stem cell and its dysregulated self-renewal, therapies for treatment of prostate cancer are likely to improve. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
9. Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery.
- Author
-
Dave, Dhiren S., Lam, John S., Leppert, John T., and Belldegrun, Arie S.
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *PROGNOSIS , *CANCER treatment , *NEPHROSTOMY , *KIDNEY surgery - Abstract
Reports on the open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. Evidence showing that nephron-sparing surgery (NSS) for patients with small tumors is equivalent to total radical nephroctomy in terms of long-term survival; Safety and efficacy of NSS; Clinical factors determining prognosis and survival in the management of the disease.
- Published
- 2005
- Full Text
- View/download PDF
10. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma
- Author
-
Lam, John S., Leppert, John T., Figlin, Robert A., and Belldegrun, Arie S.
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *MOLECULAR biology , *CLINICAL trials - Abstract
Abstract: Recent advances in the understanding of the pathogenesis, behavior, and molecular biology of renal cell carcinoma (RCC) have paved the way for developments that may enhance early diagnosis, better predict prognosis, and improve survival. Reliable predictive factors are essential for the stratification of patients into clinically meaningful categories that can be used to provide patients with counseling regarding prognosis, select treatment modalities, and determine eligibility for clinical trials. The TNM (tumor, nodes, metastasis) staging system is currently the most extensively used staging system for RCC, but it has undergone systematic revisions as a result of emerging data. Comprehensive integrated staging systems that combine important clinical and pathological variables have been created in an attempt to improve prognostication. Although staging has improved with the development of integrated systems, the incorporation of molecular tumor markers are expected to revolutionize the staging of RCC. This article reviews the important molecular markers in RCC to date and discusses their role in the diagnosis, prognostication, and therapy of patients with RCC. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
11. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.
- Author
-
Lam, John S., Leppert, John T., Belldegrun, Arie S., and Figlin, Robert A.
- Subjects
- *
ADJUVANT treatment of cancer , *CANCER treatment , *THERAPEUTICS , *RENAL cell carcinoma , *RENAL cancer , *PROGNOSIS - Abstract
Reports on the adjuvant therapy of renal cell carcinoma in patient selection and therapeutic options. Renal cell carcinoma, survival and prognostic factors; Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma; Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma; Correlations with tumor oxygen measurements and prognostic in locally advanced carcinoma of the cervix.
- Published
- 2005
- Full Text
- View/download PDF
12. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
- Author
-
Leppert, John T., Lam, John S., Pantuck, Allan J., Figlin, Robert A., and Belldegrun, Arie S.
- Subjects
- *
CARBONIC anhydrase , *RENAL cell carcinoma , *VASCULAR endothelial growth factors , *CANCER patients , *RENAL cancer , *GROWTH factors - Abstract
The use of carbonic anhydrase IX as a promising molecular marker in RCC is described by authors from Los Angeles, who discuss the promise that molecular markers hold to improve diagnosis, staging, treatment surveillance and survival of patients with RCC. There is a whole range of new treatments being introduced in the management of metastatic renal cancer. The use of VEOF-targeted therapy has particular importance, especially as it has a strong genetically linked rationale for its potential success in this area. Authors from the USA show that substantial clinical activity has been reported in initial clinical trials. In prostate cancer, drugs targeting microtubules, such as taxanes, have already been introduced clinically, and their success has received widespread attention. A new group of drugs, the epothilones, have similar but not identical binding properties to microtubules, and authors from the USA describe how they have shown activity in hormone-refractory prostate cancer, and are moving to phase III testing. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
13. Staging of renal cell carcinoma: current concepts.
- Author
-
Shvarts, Oleg, Lam, John S., Kim, Hyung L., and Belldegrun, Arie S.
- Subjects
- *
TUMOR classification , *RENAL cell carcinoma , *RENAL cancer , *KIDNEY diseases , *CANCER , *UROLOGY , *MEDICINE - Abstract
Examines the staging of renal cell carcinoma (RCC). Use of local tumor growth, lymph node involvement and distant metastasis to categorize patients with RCC by the TNM system; Increase of the size threshold for T1 tumors to seven centimeters; Comparison between T3b and T3c classification of tumors with inferior vena caval involvement.
- Published
- 2005
- Full Text
- View/download PDF
14. Update on ureteral stents
- Author
-
Lam, John S. and Gupta, Mantu
- Published
- 2004
- Full Text
- View/download PDF
15. Changing Concepts in the Surgical Management of Renal Cell Carcinoma
- Author
-
Lam, John S., Shvarts, Oleg, and Pantuck, Allan J.
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *ONCOLOGIC surgery , *KIDNEY surgery , *SURGERY - Abstract
The foundations of the generally accepted principles underlying the surgical management of renal cell carcinoma (RCC) were best annunciated in 1969 by Robson in his classic description of the radical nephrectomy [J Urol 1969;101;297]. Since then, much has changed in our understanding of the basic biology and genetics of kidney cancer, advances in renal imaging and clinical staging have led to the increased detection of incidental, lower stage, organ-confined tumors more amendable to expanded surgical options, surgical techniques themselves have evolved, and surgical equipment technology has advanced to make possible new methods of managing renal tumors in situ. Thus, the management of both localized and metastatic RCC has changed dramatically in the last 20 years, predicated on these major advancements in renal imaging, surgical techniques, and the development of effective immunotherapies for advanced disease. In this review, the evolution in thinking regarding the tenets of the radical nephrectomy will be examined, including the necessity for removal of the entire kidney, the possibility of sparing the adrenal gland, when and how extensive a lymphadenectomy should be performed, the development of laparoscopic and percutaneous nephron-sparing surgery using ablative technologies, and the role of nephrectomy and metastasectomy in patients with metastatic RCC. Here, we review current concepts and outcomes on the surgical management of RCC to help elucidate some of these changes, from the evolution of open to laparoscopic to percutaneous, from radical to partial to ablative approaches. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
16. Bacillus calmete-gue´rin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity
- Author
-
Lam, John S., Benson, Mitchell C., O’Donnell, Michael A., Sawczuk, Alexandra, Gavazzi, Anna, Wechsler, Michael H., and Sawczuk, Ihor S.
- Subjects
- *
INTERFERONS , *BLADDER cancer , *DRUG toxicity , *BCG vaccines - Abstract
Bacillus Calmette-Gue´rin (BCG) and interferon-α2B (IFN-α2B) have both been individually used for the intravesical treatment of superficial bladder cancer. We report our experience on the therapeutic efficacy and toxicity of combined intravesical BCG plus IFN-α2B for treating superficial bladder cancer, including patients failing previous BCG therapy. Thirty-two patients with superficial bladder cancer underwent 6 weekly treatments with full-, one-third, or one-tenth-dose of BCG plus 50 or 100 MU of IFN-α2B based on prior BCG exposure and tolerance. Patients with no evidence of disease proceeded onto maintenance therapy of 3 weekly treatments at 3 months followed by 2 additional maintenance cycles given 6 months apart. Response was assessed by cystoscopy/biopsy every 3 months after treatment. Before BCG plus IFN-α2B treatment, 20 patients (63%) had previously failed intravesical BCG therapy, 27 (84%) had aggressive disease (stage T1, grade 3, or carcinoma in situ), 27 (84%) had recurrent disease, 14 (44%) had multifocal disease, and 6 (19%) had disease of over 4 years duration. At median follow-up of 22 months, 21 patients (66%) remain disease-free and 11 patients (34%) had disease-recurrence. Nineteen of 32 patients (59%) were disease-free after the initial induction cycle. Six of 11 patients 55% ultimately failing combination therapy did so at the first 3 to 4 month evaluation. Four of 7 patients (57%) benefited from salvage re-induction therapy. Of the 20 patients previously treated with BCG, 12 patients (60%) remain disease-free. Combination BCG plus IFN-α2B intravesical therapy was well tolerated. Combination intravesical BCG plus IFN-α2B is an effective and tolerable alternative for patients with superficial bladder cancer, including those patients in whom intravesical BCG therapy had previously failed. Benefits of this combination therapy may include potentially less morbidity, improved clinical efficacy, and in the long term, fewer patients undergoing radical therapy. However, radical treatment options should be pursued for early failures of this combination regimen in those patients with risk factors for recurrence and progression. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
17. Impact of hydronephrosis and renal function on treatment outcome: antegrade versus retrograde endopyelotomy
- Author
-
Lam, John S., Cooper, Kimberly L., Greene, Tricia D., and Gupta, Mantu
- Subjects
- *
HYDRONEPHROSIS , *GENITOURINARY organ radiography - Abstract
: ObjectivesTo compare, in a single-surgeon, single-institution study, the efficacy of antegrade and retrograde endopyelotomy in terms of success rate and morbidity and to identify which risk factors affect treatment outcomes.: MethodsThe results were retrospectively reviewed for 88 patients with ureteropelvic junction obstruction treated with endopyelotomy. Antegrade endopyelotomy was performed with a hook knife, scissors, or cutting balloon device. Retrograde endopyelotomy was performed with a cutting balloon device. Objective results were based on intravenous urogram and/or diuretic nuclear renal scan findings, and subjective results were based on direct patient query and questionnaire.: ResultsNinety-three endopyelotomy procedures, 64 antegrade and 29 retrograde, were performed. The mean follow-up was 37.0 months (range 5 to 76). The overall success rates between antegrade and retrograde endopyelotomy (81.3% versus 75.9%) were not statistically different (P = 0.553). Patients with massive hydronephrosis and poor initial renal function were less likely to have successful endopyelotomy. Antegrade endopyelotomy, however, was more successful than retrograde endopyelotomy in patients with massive hydronephrosis (66.7% versus 20.0%; P = 0.046). The average operative time for antegrade and retrograde endopyelotomy was 93.9 and 32.7 minutes (P <0.001), respectively. The average length of hospital stay after antegrade and retrograde endopyelotomy was 3.20 and 0.14 nights (P <0.001), respectively.: ConclusionsBoth antegrade and retrograde endopyelotomy are effective treatments for ureteropelvic junction obstruction associated with minimal morbidity. Antegrade endopyelotomy appears to be more successful in patients with high-grade hydronephrosis. Retrograde endopyelotomy results in a shorter hospital stay, a shorter operative time, and less postoperative pain. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
18. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up
- Author
-
Lam, John S., Romas, Nicholas A., and Lowe, Franklin C.
- Subjects
- *
FINASTERIDE , *PROSTATE hypertrophy , *CLINICAL trials , *COMPARATIVE studies , *DRUG administration , *ENZYME inhibitors , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *BENIGN prostatic hyperplasia , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *THERAPEUTICS - Abstract
: ObjectivesTo evaluate the safety and efficacy of finasteride 5 mg during a 10-year period in men with enlarged prostates from a single center who participated in the double-blind and extension phases of the multicenter, Phase III, North American benign prostatic hyperplasia (BPH) trial. It is important that the long-term safety and efficacy of drugs intended for chronic administration in men with BPH be well understood.: MethodsThe Phase III North American BPH trial involved a 1-year, placebo-controlled, double-blind study, followed by a 5-year open extension with finasteride 5 mg/day. The trial enrolled men with symptomatic BPH, an enlarged prostate on digital rectal examination, and no evidence of prostate cancer. Of the 46 patients originally enrolled from our institution, 43 were randomized to receive finasteride or placebo, of whom 41 (95%) completed the double-blind study and entered the 5-year extension. Thirty (73%) of these 41 patients completed the 5-year extension. Patients continued to be followed up by their physicians for an additional 5 years, for a total follow-up of at least 10 years.: ResultsTwenty-four (56%) of the original 43 patients randomized to finasteride or placebo were judged as successfully treated during the 10-year finasteride follow-up (17 patients taking finasteride alone at 10 years and 7 patients who were taking finasteride alone when they discontinued during the 10-year follow-up for reasons not related to finasteride treatment). Altogether, 22 (51%) of the original 43 randomized patients continued finasteride treatment at 10 years (17 taking finasteride alone, 4 taking finasteride plus an alpha-blocker, and 1 taking finasteride for treatment of hematuria). Finasteride was well tolerated, with no new adverse experiences occurring with increasing duration of exposure to the drug.: ConclusionsThis long-term follow-up study has demonstrated that appropriately selected patients with symptomatic BPH and enlarged prostates are likely to have a long-term response to taking finasteride 5 mg daily. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
19. Editorial Comment.
- Author
-
Lam, John S.
- Subjects
- *
HEALTH websites , *MEDICAL personnel , *MEDICAL quality control , *HEALTH behavior , *COMMUNICATION , *INTERNET , *PROSTATE tumors - Published
- 2019
- Full Text
- View/download PDF
20. Use of a ureteral access sheath to facilitate removal of large stone burden during extracorporeal shock wave lithotripsy
- Author
-
Okeke, Zephaniah, Lam, John S., and Gupta, Mantu
- Subjects
- *
EXTRACORPOREAL shock wave lithotripsy , *KIDNEY stones , *EXTRACORPOREAL shock wave therapy , *KIDNEY diseases - Abstract
Large renal stone burdens within a nondilated collecting system in patients with a relative contraindication to percutaneous nephrolithotomy can be a challenging problem. We describe a novel technique using a ureteral access sheath combined with extracorporeal shock wave lithotripsy to facilitate passage of stone fragments in such patients. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
21. Using PSA kinetics to stratify risk of prostate Ca progression.
- Author
-
Lam, John S. and Belldegrun, Arie S.
- Subjects
- *
PROSTATE-specific antigen , *PHYSIOLOGICAL control systems , *BENIGN prostatic hyperplasia , *HEALTH risk assessment , *TUMOR markers , *PROSTATE cancer , *MEDICAL research - Abstract
Examines the kinetics that regulates prostate-specific antigen (PSA) by researchers from Los Angeles, California. Use of PSA kinetics to stratify risk of prostate cancer progression; Significance of the kinetics in the evaluation and treatment of patients with prostate cancer; Identification of PSA kinetics that predict distant recurrence and prostate cancer-specific mortality.
- Published
- 2005
22. Cryotherapy for localized PCa: Indications and technique.
- Author
-
Lam, John S. and Belldegrun, Arie S.
- Subjects
- *
THERAPEUTICS , *PROSTATE cancer , *CANCER in men , *CANCER , *DISEASES in men - Abstract
Provides information on cryoablation as a therapeutic option for prostate cancer. Equipment used for the procedure; Patients who are qualified for cryoablation; Strategy to maintain TRUS visibility.
- Published
- 2005
23. Young Urologists Update 2016.
- Author
-
Lam, John S. and Stroup, Sean P.
- Subjects
- *
UROLOGISTS , *UROLOGY , *CONFERENCES & conventions - Abstract
The article offers information on the annual Young Urologist Forum, that will be held during the annual meeting of the organization the American Urological Association (AUA), at the San Diego Convention Center in San Diego, California on May 9, 2016.
- Published
- 2016
24. The Burden of Ureteropelvic Junction Obstruction in the United States.
- Author
-
Lam, John S. and Schulam, Peter G.
- Subjects
- *
URETERIC obstruction , *PELVIC diseases , *HYDRONEPHROSIS , *URETER diseases - Abstract
The article offers a look at the prevalence of ureteropelvic junction obstruction (UPJO) in the U.S. UPJO is a condition referring to a blockage at the junction of the renal pelvis and the ureter, which causes prenatal and neonatal hydronephrosis. Between 1997 and 2000, hospitalization rates for UPJO were higher for males than for females. The article includes information on hospital length of stay, physician visits and treatment of UPJO.
- Published
- 2007
25. The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy
- Author
-
Leppert, John T., Lam, John S., Butch, Anthony W., and Belldegrun, Arie S.
- Published
- 2006
- Full Text
- View/download PDF
26. Young Urologists Update 2015.
- Author
-
Lam, John S. and Yates, Jennifer
- Subjects
- *
UROLOGISTS , *COMMITTEES , *FORUMS , *SOCIETIES - Abstract
The article discusses the establishment of the American Urological Association Young Urologists Committee with representation from association Sections, the Society of Government Service Urologists and osteopathic urologists. It also provides information on "The Prescription for Financial Health" presentation of MEDIQUS Asset Advisors, Inc. chief executive officer Ronald J. Paprocki at the Young Urologists Forum during the 2015 AUA Annual Meeting in New Orleans on May 18, 2015.
- Published
- 2015
27. Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality
- Author
-
Karakiewicz, Pierre I., Trinh, Quoc-Dien, Lam, John S., Tostain, Jacques, Pantuck, Allan J., Belldegrun, Arie S., and Patard, Jean-Jacques
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *CANCER diagnosis , *HEMOGLOBINS , *DIAGNOSIS ,BLOOD platelet examination - Abstract
Abstract: Objective: Anaemia and/or thrombocytosis were identified as independent predictors of poor survival in renal cell carcinoma (RCC). We tested the extent to which these markers worsen the prognosis in these patients. Methods: Analyses targeted 1828 patients with renal cell carcinoma. Univariable, multivariable, and predictive accuracy analyses addressed RCC-specific mortality (RCC-SM). Results: In univariable and multivariable analyses, both platelet count and preoperative haemoglobin level were statistically significant predictors of RCC-SM. However, neither platelet count nor preoperative haemoglobin level increased the combined multivariable accuracy of established RCC-SM (predictive accuracy gain=0.3%) predictors. Conclusions: Patients who present with severe anaemia or elevated platelets are at no higher risk of RCC-SM than that related to their stage, grade, histologic subtype, and Eastern Cooperative Oncology Group-Performance Status. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
28. Use of Haemostatic Agents and Glues during Laparoscopic Partial Nephrectomy: A Multi-Institutional Survey from the United States and Europe of 1347 Cases▪
- Author
-
Breda, Alberto, Stepanian, Sevan V., Lam, John S., Liao, Joseph C., Gill, Inderbir S., Colombo, Jose R., Guazzoni, Giorgio, Stifelman, Michael D., Perry, Kent T., Celia, Antonio, Breda, Guglielmo, Fornara, Paolo, Jackman, Stephen V., Rosales, Antonio, Palou, Juan, Grasso, Michael, Pansadoro, Vincenzo, Disanto, Vincenzo, Porpiglia, Francesco, and Milani, Claudio
- Subjects
- *
LAPAROSCOPIC surgery , *KIDNEY tumors , *SURGICAL complications , *HEMOSTATICS , *HEMORRHAGE , *URINATION disorders , *UROLOGISTS , *SURVEYS - Abstract
Abstract: Objectives: Laparoscopic partial nephrectomy (LPN) is a technically challenging procedure for the management of renal tumours. Major complications of LPN include bleeding and urine leakage. Haemostatic agents (HAs) and/or glues may reduce haemorrhage and urine leakage. We sought to examine the current practice patterns for urologists performing LPN with regard to HA use and its relationship with bleeding and urine leakage. Materials and methods: A survey was sent via e-mail to urologists currently performing LPN in centres in the United States and Europe. We queried the indications for HA/glue usage, type of HAs/glues used, and whether concomitant suturing/bolstering was performed. In addition, the total number of LPNs performed, laparoscopic tools used to resect the tumour, tumour size, and tumour position were queried. Results: Surveys suitable for analysis were received from 18 centres (n =1347 cases). HAs and/or glues were used in 1042 (77.4%) cases. Mean tumour size was 2.8cm, with 79% of the tumours being defined as exophytic and 21% deep. The HAs and glues used included gelatin matrix thrombin (FloSeal), fibrin gel (Tisseel), bovine serum albumin (BioGlue), cyanoacrylate glue (Glubran), oxidized regenerated cellulose (Surgicel), or combinations of these. Sixteen centres performed concomitant suturing/bolstering. The overall postoperative bleeding requiring transfusion and urine leakage rates were 2.7% and 1.9%, respectively. Conclusions: The use of HAs and/or glues is routine in most centres performing LPN. The overall haemorrhage and urine leakage rates are low following LPN. More studies are needed to assess the potential role of HAs and/or glues in LPN. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
29. RENCA/carbonic anhydrase-IX: A murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma
- Author
-
Shvarts, Oleg, Janzen, Nicolette, Lam, John S., Leppert, John T., Caliliw, Randy, Figlin, Robert A., Belldegrun, Arie S., and Zeng, Gang
- Subjects
- *
RENAL cancer , *RENAL cell carcinoma , *CANCER invasiveness , *CELL membranes - Abstract
Objectives: Carbonic anhydrase-IX (CA-IX) is a cell surface tumor-associated antigen expressed by most clear cell renal cell carcinomas (RCCs). The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC.Methods: A retrovirus encoding the human CA-IX gene was used to transduce the murine RCC line, RENCA. In vivo growth kinetics and CA-IX expression were compared between RENCA and RENCA/CA-IX using heterotopic, metastatic, and orthotopic models.Results: Transduction of RENCA created the RENCA/CA-IX line with nearly 100% CA-IX surface expression. In the heterotopic model, subcutaneous injection of 500,000 and 50,000 cells led to tumor formation at 2 to 2.5 weeks after injection, with similar growth kinetics between the two cell lines at either cell number. In the pulmonary metastatic model, a similar number of metastases was noted after inoculation of RENCA and RENCA/CA-IX. In the orthotopic model, autopsy revealed a CA-IX-expressing renal tumor, as well as CA-IX-expressing metastases to the lungs, liver, contralateral kidney, intestines, and lymph nodes. In all the above models, the RENCA/CA-IX tumors retained expression of CA-IX, as demonstrated by immunohistochemistry staining.Conclusions: RENCA/CA-IX is the first tumor model that manifests in immunocompetent Balb/c mice and stably expresses a defined kidney cancer-associated antigen. It maintains antigen expression, forms metastases, and produces reliable tumor growth kinetics equivalent to that of its parental cell line. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
30. Young Urologists Committee: What's New in 2017.
- Author
-
Dorin, Ryan P., Stroup, Sean P., and Lam, John S.
- Subjects
- *
UROLOGY , *UROLOGISTS , *OSTEOPATHIC physicians , *CONFERENCES & conventions - Published
- 2017
31. Unclassified renal cell carcinoma: an analysis of 85 cases.
- Author
-
Karakiewicz, Pierre I., Hutterer, Georg C., Trinh, Quoc-Dien, Pantuck, Allan J., Klatte, Tobias, Lam, John S., Guille, Francois, de La Taille, Alexandre, Novara, Giacomo, Tostain, Jacques, Cindolo, Luca, Ficarra, Vincenzo, Schips, Luigi, Zigeuner, Richard, Mulders, Peter F., Chautard, Denis, Lechevallier, Eric, Valeri, Antoine, Descotes, Jean-Luc, and Lang, Herve
- Subjects
- *
RENAL cell carcinoma , *KIDNEY surgery , *CANCER patients , *TUMORS , *MORTALITY , *CANCER invasiveness , *MULTIVARIATE analysis - Abstract
OBJECTIVES To compare cancer-specific mortality in patients with unclassified renal cell carcinoma (URCC) vs clear cell RCC (CRCC) after nephrectomy, as URCC is a rare but very aggressive histological subtype. PATIENTS AND METHODS Eighty-five patients with URCC and 4322 with CRCC were identified within 6530 patients treated with either radical or partial nephrectomy at 18 institutions. Of 85 patients with URCC, 55 were matched with 166 of 4322 for grade, tumour size, and Tumour, Node and Metastasis stages. Kaplan-Meier and life-table analyses were used to address RCC-specific survival. Subsequently, multivariate Cox regression analyses were used to test for differences in RCC-specific survival in unmatched samples. RESULTS Of patients with URCC, 80% had Fuhrman grades III or IV, vs 37.8% for CRCC. Moreover, 36.5% of patients with URCC had pathologically confirmed nodal metastases, vs 8.6% with CRCC. Finally, 54.1% of patients with URCC had distant metastases at the time of nephrectomy, vs 16.8% with CRCC. Despite these differences in the overall analyses, after matching for tumour characteristics, the URCC-specific mortality rate was 1.6 times higher ( P = 0.04) in matched analyses and 1.7 times higher ( P = 0.001) in multivariate analyses. CONCLUSIONS These findings indicate that URCC presents with a higher stage and grade, and even after controlling for the stage and grade differences, predisposes patients to 1.6–1.7 times the mortality of CRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
32. Morbidity and Clinical Outcome of Nephron-Sparing Surgery in Relation to Tumour Size and Indication▪
- Author
-
Patard, Jean-Jacques, Pantuck, Allan J., Crepel, Maxime, Lam, John S., Bellec, Laurent, Albouy, Baptiste, Lopes, David, Bernhard, Jean-Christophe, Guillé, François, Lacroix, Bertrand, De La Taille, Alexandre, Salomon, Laurent, Pfister, Christian, Soulié, Michel, Tostain, Jacques, Ferriere, Jean-Marie, Abbou, Claude C., Colombel, Marc, and Belldegrun, Arie S.
- Subjects
- *
KIDNEY tubules , *TUMORS , *CANCER , *SURGERY , *BLOOD transfusion - Abstract
Abstract: Objective: To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication. Methods: The study included patients from eight international academic centres. Age, sex, TNM stage, tumour size, Fuhrman grade, Eastern Cooperative Oncology Group performance status (ECOG-PS), surgical margins, local and distant recurrences, and overall and cancer-specific survival rates were collected and analysed. Indication for elective or mandatory NSS, medical and surgical complication rates, mean blood loss, blood transfusion, and length of hospital stay were specifically recorded for the purpose of this study. Groups were compared for qualitative and quantitative variables by using χ2 (Fischer exact test) and Student t tests, respectively. Results: A total of 1048 NSS procedures were included in this study. Mean tumour size was 3.4±2.1cm. In 730 elective procedures mean operative time (p =0.002), mean blood loss (p =0.01), the need for blood transfusion (p =0.001), and urinary fistula rate (p =0.01) were significantly increased for tumours >4cm. However, these differences did not result in significantly increased medical (p =0.4), surgical complication rates (p =0.6), or length of hospital stay (p =0.9). Finally, in elective procedures for malignant tumours, positive surgical margins, local or distant recurrence rates, and cancer-specific survival were not significantly different in tumours ≤4cm and >4cm. Conclusion: Excellent cancer control and outcomes can be achieved with NSS in carefully selected patients with tumours >4cm. Expanding the size indication of elective NSS results in an increased but acceptable morbidity. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
33. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.
- Author
-
Klatte, Tobias, Wunderlich, Heiko, Patard, Jean-Jacques, Kleid, Mark D., Lam, John S., Junker, Kerstin, Schubert, Jörg, Böhm, Malte, Allhoff, Ernst P., Kabbinavar, Fairooz F., Crepel, Maxime, Cindolo, Luca, De La Taille, Alexandre, Tostain, Jacques, Mejean, Arnaud, Soulie, Michel, Bellec, Laurent, Bernhard, Jean Christophe, Ferriere, Jean-Marie, and Pfister, Christian
- Subjects
- *
RENAL cell carcinoma , *LACTATE dehydrogenase , *CANCER research , *CLINICAL trials , *MEDICAL centers - Abstract
An interesting group of papers in this section is headed by two papers on synchronous bilateral renal tumours, one from an international group of authors and one from Germany. The large series of patients are examined carefully by both groups, and the findings should be useful for all who are interested in this area. Authors from the UK examine the role of lactate dehydrogenase as a prognostic factor for testicular cancer. They found that it had limited sensitivity, specificity and positive predictive value for detecting relapse, with false-positive elevations being common. OBJECTIVE To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited. PATIENTS AND METHODS We retrospectively studied 10 337 patients from 12 urological centres to identify patients with N0M0 synchronous bilateral RCC; the clinicopathological features and cancer-specific survival were compared to a cohort treated for N0M0 unilateral RCC. RESULTS In all, 153 patients had synchronous bilateral solid renal tumours, of whom 135 (88%) had synchronous bilateral RCC, 118 with nonmetastatic disease; 91% had nonfamilial bilateral RCC. Bilateral clear cell RCC was the major histological subtype (76%), and papillary RCC was the next most frequent (19%). Multifocality was found in 54% of bilateral RCCs. Compared with unilateral RCC, patients did not differ in Eastern Cooperative Oncology Group performance status (ECOG PS) and T classification, but bilateral RCCs were more frequently multifocal (54% vs 16%, P < 0.001) and of the papillary subtype (19% vs 12%), and less frequently clear cell RCC (76% vs 83%, P = 0.005). For the outcome, patients with nonmetastatic synchronous bilateral RCC and unilateral RCC had a similar prognosis ( P = 0.63); multifocality did not affect survival ( P = 0.60). Multivariate analysis identified ECOG PS, T classification, and Fuhrman grade, but not laterality, as independent prognostic factors for cancer-specific survival. CONCLUSIONS Patients with N0M0 synchronous bilateral RCC and N0M0 unilateral RCC have a similar prognosis. The frequency of a familial history for RCC (von Hippel-Lindau disease or familial RCC) was significantly greater in bilateral synchronous than in unilateral RCC. The significant pathological findings in synchronous bilateral RCC are papillary subtype and multifocality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
34. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma.
- Author
-
Klatte, Tobias, Chung, JinSoo, Leppert, John T., Lam, John S., Pantuck, Allan J., Figlin, Robert A., and Belldegrun, Arie S.
- Subjects
- *
RENAL cell carcinoma , *RENAL cancer , *CANCER , *DATABASES , *CANCER patients - Abstract
OBJECTIVE To define the prognostic relevance of capsular involvement (invasion with no penetration) and collecting-system invasion in patients with stage I (pT1N0M0) and stage II (pT2N0M0) renal cell carcinoma (RCC), by evaluating the outcome of patients treated with nephrectomy. PATIENTS AND METHODS In all, 519 patients from a kidney cancer database treated with nephrectomy for stage I and II RCC between 1985 and 2005 were assessed retrospectively. The primary endpoint was recurrence-free survival time. The prognostic relevance of capsular involvement and collecting-system invasion were examined using univariate and multivariate survival analysis. RESULTS Capsular involvement and collecting-system invasion were evident in 112 (21.6%) and 39 (7.5%) patients, respectively. Capsular involvement was associated with higher Fuhrman grades and larger tumours. The incidence of collecting-system invasion was higher in patients with microvascular invasion. The median follow-up was 49 months. In univariate analysis, patients with capsular involvement and collecting-system invasion had a worse prognosis than patients without ( P = 0.007 and <0.001, respectively). In multivariate analysis, capsular involvement (hazard ratio 1.84, P = 0.036) and collecting-system invasion (3.78, P < 0.001) were independent prognostic factors of recurrence-free survival. Interestingly, there was no survival difference between patients with capsular involvement in stage I/II and patients with invasion of perinephric tissue (pT3aN0M0). CONCLUSIONS These findings suggest that capsular involvement and collecting-system invasion are poor prognostic findings in stage I and II RCC. They should both be considered when planning the follow-up. A revised pT3a stage including patients with capsular involvement could improve its prognostic validity. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
35. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
- Author
-
Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, Sawczuk IS, Lam, John S, Benson, Mitchell C, O'Donnell, Michael A, Sawczuk, Alexandra, Gavazzi, Anna, Wechsler, Michael H, and Sawczuk, Ihor S
- Abstract
Bacillus Calmette-Guérin (BCG) and interferon-alpha2B (IFN-alpha2B) have both been individually used for the intravesical treatment of superficial bladder cancer. We report our experience on the therapeutic efficacy and toxicity of combined intravesical BCG plus IFN-alpha2B for treating superficial bladder cancer, including patients failing previous BCG therapy. Thirty-two patients with superficial bladder cancer underwent 6 weekly treatments with full-, one-third, or one-tenth-dose of BCG plus 50 or 100 MU of IFN-alpha2B based on prior BCG exposure and tolerance. Patients with no evidence of disease proceeded onto maintenance therapy of 3 weekly treatments at 3 months followed by 2 additional maintenance cycles given 6 months apart. Response was assessed by cystoscopy/biopsy every 3 months after treatment. Before BCG plus IFN-alpha2B treatment, 20 patients (63%) had previously failed intravesical BCG therapy, 27 (84%) had aggressive disease (stage T1, grade 3, or carcinoma in situ), 27 (84%) had recurrent disease, 14 (44%) had multifocal disease, and 6 (19%) had disease of over 4 years duration. At median follow-up of 22 months, 21 patients (66%) remain disease-free and 11 patients (34%) had disease-recurrence. Nineteen of 32 patients (59%) were disease-free after the initial induction cycle. Six of 11 patients 55% ultimately failing combination therapy did so at the first 3 to 4 month evaluation. Four of 7 patients (57%) benefited from salvage re-induction therapy. Of the 20 patients previously treated with BCG, 12 patients (60%) remain disease-free. Combination BCG plus IFN-alpha2B intravesical therapy was well tolerated. Combination intravesical BCG plus IFN-alpha2B is an effective and tolerable alternative for patients with superficial bladder cancer, including those patients in whom intravesical BCG therapy had previously failed. Benefits of this combination therapy may include potentially less morbidity, improved clinical efficacy, and in the long term, fewer patients undergoing radical therapy. However, radical treatment options should be pursued for early failures of this combination regimen in those patients with risk factors for recurrence and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
36. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.
- Author
-
Kaplan, Steven A, Ghafar, Mohamed A, Volpe, Michael A, Lam, John S, Fromer, Debra, and Te, Alexis E
- Subjects
- *
CLINICAL trials , *COMPARATIVE studies , *ENZYME inhibitors , *FINASTERIDE , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *NEEDLE biopsy , *PALPATION , *PHARMACOLOGY , *PROSTATE , *PROSTATE tumors , *RESEARCH , *TUMOR classification , *PROSTATE-specific antigen , *EVALUATION research , *PHARMACODYNAMICS - Abstract
Objectives: To determine, in a prospective study, the prostate-specific antigen (PSA) response to finasteride challenge in men with a serum PSA greater than 4 ng/mL who had undergone previous biopsy. Patients with a serum PSA level greater than 4 ng/mL who have undergone repeated prostate biopsy with prostate cancer (CaP) that was not detected present a diagnostic dilemma. The magnitude of PSA reduction after administration of finasteride has been well documented. In addition, doubling of the PSA value after 1 year of finasteride has been touted to be a more useful paradigm for diagnosing CaP than PSA alone.Methods: Thirty-eight men with a baseline serum PSA level greater than 4 ng/mL and a normal digital rectal examination who had been previously biopsied a minimum of two times, with CaP not detected, were given 5 mg finasteride daily. The PSA level was measured at 6 and 12 months with repeat transrectal ultrasonography and biopsy (12 cores) performed at 1 year. Changes in prostate volume, serum PSA, PSA density, and the incidence of CaP at 1 year were assessed.Results: The mean age of the group was 60.5 years (+/-7.6). For the group, the average number of previous biopsies performed was 2.9 (range 2 to 6). The baseline PSA level for the entire group was 6.32 ng/mL (+/-3.2), and the baseline prostate volume was 37.3 cm3 (+/-12.4). At 1 year, the PSA level had decreased to 3.73 ng/mL (-41.0%), and the prostate volume had decreased to 30.4 cm3 (-18.5%). In the 11 men (29%) in whom CaP was detected, the serum PSA decreased from 7.3 to 5.2 ng/mL (-28.8%) and the prostate volume decreased from 37.3 to 32.3 cm3 (-13.4%). CaP was detected in 0 of 10 men with a serum PSA decrease of 50% or higher, in 6 (32%) of 19 men with a PSA decrease between 33% and 50%, and in 5 (56%) of 9 men who had a PSA decrease of less than 33%.Conclusions: The data in this preliminary study suggest that the magnitude of change in serum PSA after 1 year of finasteride challenge may be useful in diagnosing CaP in patients with elevated PSA levels and prior negative prostate biopsy. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.